Monitor updates from Pfizer regarding regulatory submissions for LB6V (Lyme vaccine), which could be a significant catalyst if accepted by regulators. The conferences may provide additional color on pipeline progress, but no near-term stock-moving news is expected from this filing alone.
VALN drugs
VALN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $5.95entry
- T+1 · 6mo ago −5.38%α −5.52% · $5.63
- T+5 · 5mo ago −7.90%α −5.15% · $5.48
- T+20 · 5mo ago −12.10%α −10.80% · $5.23
- T+60 · 3mo ago +13.95%α +12.72% · $6.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Valneva announced participation in investor conferences (Jefferies, Oddo BHF, BNP Paribas) and a travel medicine conference, with key discussion topics including its commercial vaccines and the Lyme disease candidate LB6V (partnered with Pfizer, which reported positive Phase 3 results and plans regulatory submissions). This is a routine update with no material financial or operational data.
Key Facts
- Valneva to present and hold investor meetings at Jefferies Global Healthcare Conference (June 3), Oddo BHF Nextcap Forum (June 12), and BNP Paribas SMID Cap Conference (June 24).
- LB6V (Lyme disease vaccine candidate) partnered with Pfizer; Pfizer reported positive Phase 3 results and plans regulatory submissions.
- Valneva will be a Gold Sponsor at the 10th Northern European Conference on Travel Medicine (June 3-5).
- No financial figures or guidance were disclosed in the filing.
Financial Impact
No financial impact disclosed; event is a routine conference participation announcement.
Risk Factors
- Regulatory submissions for LB6V may face delays or unfavorable outcomes.
- Commercial vaccine sales may underperform expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-039308 |
| Document: a6-kcoverpagetemplate.htm | 0001628280-26-039308 |
| Document: 0001628280-26-039308-index-headers.html | 0001628280-26-039308 |
| Document: 0001628280-26-039308-index.html | 0001628280-26-039308 |
| Document: 0001628280-26-039308.txt | 0001628280-26-039308 |
Track record
9 reports on VALN
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $5.66 Now $5.65 −0.18% settles Dec 14
- Nov 6, 202610d ago 6-K Neutral 2/10 Entry $5.51 Now $5.65 +2.54% settles Dec 7
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $5.91 to $5.76 Now $5.65 −4.40% ▼ −2.54% −0.64% vs SPY
- Oct 8, 20265w ago 6-K Neutral 3/10 Entry $5.69 to $5.64 Now $5.65 −0.70% ▼ −0.88% +4.41% vs SPY
- Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $5.35 to $5.08 Now $5.65 +5.61% ▼ −5.05% −6.36% vs SPY
- Jun 5, 202623w ago 6-K Neutral 2/10 Entry $5.48 to $5.40 Now $5.65 +3.10% ▼ −1.46% −3.32% vs SPY
- Jun 1, 202624w ago 6-K Neutral 2/10 Viewing Entry $5.95 to $5.23 Now $5.65 −5.04% ▼ −12.10% −10.80% vs SPY
- May 5, 202627w ago 6-K Neutral 2/10 Entry $5.29 to $5.63 Now $5.65 +6.81% ▲ +6.43% +1.47% vs SPY
- Mar 26, 202633w ago 6-K Neutral 3/10 Entry $6.32 to $5.50 Now $5.65 −10.60% ▼ −12.97% −23.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers